Back |
home / stock / mtfb / mtfb message board
Subject | By | Source | When |
---|---|---|---|
Good observation....let's see if we have a filing | $$$MADE | investorshub | 03/20/2019 8:13:16 PM |
Let's see what happens here at $2.50. I | cjstocksup | investorshub | 03/20/2019 7:26:30 PM |
Going up. | Heu333 | investorshub | 03/20/2019 6:48:57 PM |
got in at 2.62 and will see what | nokomis | investorshub | 03/20/2019 6:43:48 PM |
LOVE IT!! The Company also has plans to | $$$MADE | investorshub | 03/20/2019 6:18:09 PM |
slow grind back down | TheFinalCD | investorshub | 03/20/2019 3:56:27 PM |
$MTFB boom. Mentioned sub $2 on Twitter | Longer Than Most | investorshub | 03/20/2019 3:05:58 PM |
$3.28 weeeeeeeeeee! BOOM! | $$$MADE | investorshub | 03/20/2019 2:15:04 PM |
$3 added... | $$$MADE | investorshub | 03/20/2019 2:11:50 PM |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB) ("Motif Bio" or the "Company") announces that formal notice was given by the Company to Nasdaq on November 25, 2019 of the intention to voluntarily delist the Company’s American Depository Shares (ADSs)...
NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will be utilising NIAID’s 1 suite of preclinical services through JMI Laboratories ...
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that its Lender, Hercules Capital, Inc., has agreed to amend the Company’s loan and security agreemen...